The US FTC conditionally clears the transaction between two neurosurgical companies (Integra / Johnson & Johnson)

What Happened: On February 14, 2017, Integra agreed to purchase Johnson & Johnson’s Codman neurosurgery business (excluding Codman’s neurovascular and drug deliver businesses) for $1.045 billion. Seven months later, on September 25, 2017, the Federal Trade Commission (FTC) agreed to clear the transaction subject to the parties divesting five neurosurgical tools and associated assets including the relevant intellectual property (IP), manufacturing technology and know-how, and research & development (R&D) information related to the five tools. Additionally the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • United Kingdom’s Competition Authority - CMA (London)
  • McDermott Will & Emery (Washington)

Quotation

Louise Aberg, Gregory E. Heltzer, The US FTC conditionally clears the transaction between two neurosurgical companies (Integra / Johnson & Johnson), 25 September 2017, e-Competitions Merger Remedies, Art. N° 93068

Visites 57

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues